| Novartis announces oncology conference focus | Posted on 16/05/2008 in Pharmaceutical Company Product News The latest data on Novartis's cancer treatment RAD001, or everolimus, will be a key feature of the company's presentations at the annual meeting of the American Society of Clinical Oncology.
Novartis hopes the drug is a new treatment option for patients with advanced kidney cancer that has not responded to standard therapies.
The late-breaking data will be presented orally to delegates at the meeting, which is in its 44th year.
Novartis plans to give a comprehensive overview of its research and development in more than 170 abstracts, including details of the first efficacy results from the ABCSG-12 study into the impact of Zometa on total remission in patients who have had early breast cancer.
President and chief executive of the firm's oncology unit, David Epstein, said: "This is a particularly exciting year for Novartis Oncology in advancing research and touching the lives of thousands of cancer patients."
Novartis's areas of focus are cardiovascular and metabolism, oncology and haematology, neuroscience and ophthalmics, respiratory, immunology and infectious diseases.Other news stories from 16/05/2008
Read more in the Zenopa News Archive
How this news is generated
|  |
|
